E D Crawford

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO Electronic address
    Urology 83:1122-8. 2014
  2. pmc Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, CO, USA
    Cancer Manag Res 3:201-9. 2011
  3. pmc Leuprorelin depot injection: patient considerations in the management of prostatic cancer
    Zinelabidine Abouelfadel
    Urologic Oncology, University of Colorado Cancer Center Aurora, CO, USA
    Ther Clin Risk Manag 4:513-26. 2008
  4. ncbi request reprint Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
  5. ncbi request reprint Southwest Oncology Group studies in bladder cancer
    E David Crawford
    Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 97:2099-108. 2003
  6. doi request reprint Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
  7. ncbi request reprint A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
  8. ncbi request reprint Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  9. ncbi request reprint Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
  10. ncbi request reprint Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    J Urol 175:1422-6; discussion 1426-7. 2006

Research Grants

Detail Information

Publications104 found, 100 shown here

  1. ncbi request reprint Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix
    E David Crawford
    Department of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, CO Electronic address
    Urology 83:1122-8. 2014
    ..To demonstrate the safety and efficacy of up to 5 years of degarelix treatment and the effects of crossing over from leuprolide to degarelix in the extension phase of a phase III pivotal 1-year trial...
  2. pmc Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, CO, USA
    Cancer Manag Res 3:201-9. 2011
    ..We recommend further research, including head-to-head trials between the 6-month GnRH depots, to refine our understanding of these products...
  3. pmc Leuprorelin depot injection: patient considerations in the management of prostatic cancer
    Zinelabidine Abouelfadel
    Urologic Oncology, University of Colorado Cancer Center Aurora, CO, USA
    Ther Clin Risk Manag 4:513-26. 2008
    ....
  4. ncbi request reprint Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:13-9. 2003
    ....
  5. ncbi request reprint Southwest Oncology Group studies in bladder cancer
    E David Crawford
    Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 97:2099-108. 2003
    ..SWOG accomplishments in bladder cancer are highlighted, and future strategies are discussed...
  6. doi request reprint Understanding the epidemiology, natural history, and key pathways involved in prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Science Center, Denver, Colorado, USA
    Urology 73:S4-10. 2009
    ..A substantial research effort has recently focused on understanding the pathways involved in the disease's emergence and progression, particularly the 5alpha-reductase pathway...
  7. ncbi request reprint A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer
    E David Crawford
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    J Urol 175:533-6. 2006
    ..The safety, efficacy and pharmacokinetics of LA-2585, a new 6-month subcutaneous depot of leuprolide acetate (Atrix Laboratories, Fort Collins, Colorado) were investigated in patients with prostate cancer...
  8. ncbi request reprint Prostate cancer. Introduction
    E David Crawford
    Division of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:1-2. 2003
  9. ncbi request reprint Epidemiology of prostate cancer
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center and the University of Colorado Cancer Center, Denver, Colorado 80262, USA
    Urology 62:3-12. 2003
    ..In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans...
  10. ncbi request reprint Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    J Urol 175:1422-6; discussion 1426-7. 2006
    ..We analyzed data from the placebo arm of the MTOPS trial to determine clinical predictors of BPH progression...
  11. ncbi request reprint Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, Washington, DC, USA
    J Urol 175:1286-90; discussion 1290. 2006
    ..A large fraction of screened men have low (less than 2 ng/ml) initial PSA. The yield over time of positive PSA screens (ie more than 4 ng/ml) in these men has not been well characterized in large cohorts in the United States...
  12. ncbi request reprint Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile
    E David Crawford
    University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    BJU Int 95:1-5. 2005
  13. ncbi request reprint PSA testing: what is the use?
    E David Crawford
    University of Colorado, Denver, CO 80262, USA
    Lancet 365:1447-9. 2005
  14. ncbi request reprint Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values
    E D Crawford
    Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA
    Prostate 38:296-302. 1999
    ..0 ng/ml or an age-specific reference range (ASRR) as an abnormal cutoff PSA value...
  15. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  16. ncbi request reprint Herbal and vitamin supplement use in a prostate cancer screening population
    Albaha Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 63:288-92. 2004
    ....
  17. ncbi request reprint Artificial neural network model to predict biochemical failure after radical prostatectomy
    C Porter
    Department of Urology, Veterans Affairs Medical Center, Washington, DC, USA
    Mol Urol 5:159-62. 2001
    ..81. CONCLUSION: These results suggest that ANN models can predict PSA failure using readily available preoperative variables. Such predictive models may offer assistance to patients and physicians deciding on definitive therapy for CaP...
  18. ncbi request reprint Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
    ..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
  19. ncbi request reprint High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade
    Zinelabidine Abouelfadel
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Prostate Cancer 1:115-7. 2002
    ..Continued screening for prostate cancer is resulting in the diagnosis of more unfavorable cancers...
  20. ncbi request reprint Recent advances in hormonal therapy for advanced prostate cancer
    Siam Oottamasathien
    Department of Surgery, Division of Urology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:1047-52; discussion 1054-8. 2003
    ..Although hormonal therapy is an important treatment modality for advanced prostate cancer, long-term treatment carries significant side effects that need to be considered...
  21. ncbi request reprint Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW)
    A Barqawi
    Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 800010 0510, USA
    Int J Impot Res 17:370-4. 2005
    ..Moreover, race appears to constitute another neglected potential risk factor, which should be investigated further in future studies...
  22. ncbi request reprint Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network
    A M Ziada
    University of Colorado Health Sciences Center, Denver, Colorado 80602, USA
    Cancer 91:1653-60. 2001
    ..Continued investigation of this approach with larger data sets seems warranted...
  23. ncbi request reprint Early versus late hormonal therapy: debating the issues
    E David Crawford
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Science Center, Denver, Colorado 80010, USA
    Urology 61:8-13. 2003
    ..Thus, accumulating evidence provides a rationale for continued investigation into the use of early hormonal therapy in selected patients...
  24. ncbi request reprint Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  25. doi request reprint Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up
    Lionel L Banez
    Division of Urologic Surgery and the Duke Prostate Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 104:310-4. 2009
    ....
  26. ncbi request reprint Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    A Barqawi
    Section of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Int J Impot Res 18:323-8. 2006
    ..Current recommendations are to exclude prostate cancer before initiating TRT in men over age 40 and to closely monitor men in the first year of testosterone replacement, followed by observation in subsequent years...
  27. ncbi request reprint Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer
    E David Crawford
    University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 21:27-32; discussion 33-4, 39. 2007
    ..In this review, we present the current status of our knowledge about this procedure and the most important challenges that need to be addressed. We also present the initial results with this approach at our center...
  28. ncbi request reprint The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer
    A Barqawi
    University of Colorado Cancer Center, and Urologic Oncology, University of Colorado Health Sciences Center, Denver, CO 80261, USA
    BJU Int 92:695-8. 2003
    ....
  29. ncbi request reprint Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer
    J T Batuello
    Artificial Neural Networks in CaP Project and the, Denver, Colorado 80209, USA
    Urology 57:481-5. 2001
    ..The risk curve provides a clinically useful tool that can be used to give patients a realistic assessment of their risk of LN spread...
  30. ncbi request reprint Terazosin, doxazosin, and prazosin: current clinical experience
    B Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, Colorado Health Science Center, Denver, Colorado 80262, USA
    Urology 58:49-54. 2001
    ..Pharmacokinetic activity, mode of action, clinical efficacy, and side effects of the selective alpha(1)-receptor blockers terazosin, doxazosin, and prazosin are reviewed...
  31. ncbi request reprint Controversies of androgen ablation therapy for metastatic prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, 1665 North Ursula, Aurora, CO 80010, USA
    Curr Pharm Des 12:799-805. 2006
    ....
  32. doi request reprint Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
    ..Southwest Oncology Group (SWOG) study 9921 is a randomized, phase III, intergroup study to define the role of adjuvant chemotherapy in patients with high-risk prostate cancer...
  33. ncbi request reprint Preventing and treating the complications of hormone therapy
    Ravi J Kumar
    Urologic Oncology, University of Colorado Health Sciences Center, 4200 East 9th Avenue C 319, Denver, CO 80262, USA
    Curr Urol Rep 6:217-23. 2005
    ....
  34. ncbi request reprint Genitourinary malignancies
    Shandra S Wilson
    Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA
    Cancer Chemother Biol Response Modif 22:485-513. 2005
  35. doi request reprint The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions
    Natalie J Serkova
    Department of Anesthesiology and Radiology, Biomedical MRI MRS, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Prostate 68:620-8. 2008
    ..In this study, proton nuclear magnetic resonance spectroscopy ((1)H-NMRS) is used to assess potential metabolic markers of prostate cancer (PCa) in human expressed prostatic secretions (EPS)...
  36. ncbi request reprint A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CO 80045 0511, USA
    Cancer 107:266-74. 2006
    ..Preclinical data from prostate cancer cell lines suggested a synergistic effect of these therapies...
  37. ncbi request reprint The current use and future trends of focal surgical therapy in the management of localized prostate cancer
    Al B Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, CO, USA
    Cancer J 13:313-7. 2007
    ..In addition, we will discuss future promising tools in MIT such as photodynamic therapy and the target focal therapy approach as a new trend for the treatment of organ-confined low-volume disease...
  38. ncbi request reprint Screening for prostate cancer in 2006: PSA in the 21st century
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, USA
    N C Med J 67:136-9. 2006
  39. ncbi request reprint The association of time of day and serum testosterone concentration in a large screening population
    E David Crawford
    Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
    BJU Int 100:509-13. 2007
    ....
  40. ncbi request reprint The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms
    Al Baha Barqawi
    Urologic Oncology Department, School of Medicine, University of Colorado Health Science Center, Denver, Colorado, USA
    BJU Int 100:853-7. 2007
    ..To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)...
  41. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  42. ncbi request reprint Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program
    Al Baha Barqawi
    Section of Urologic Oncology, University of Colorado Health Science Center School of Medicine, Denver, Colorado, USA
    Urology 65:708-12. 2005
    ..To assess the effect of aging and body mass index (BMI) on both serum total prostate-specific antigen (tPSA) and complexed PSA (cPSA) from the results of the 2003 Prostate Cancer Awareness Week national screening database...
  43. ncbi request reprint Focal therapy in prostate cancer: future trends
    Al Barqawi
    University of Colorado Health Sciences Center, 4200 E 9th Ave, C 319, Denver, Colorado 80262, USA
    BJU Int 95:273-4. 2005
  44. ncbi request reprint Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    L Michael Glode
    Oncology Urology Department, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer 98:1643-8. 2003
    ....
  45. ncbi request reprint Artificial neural networks for predictive modeling in prostate cancer
    Eduard J Gamito
    University of Colorado Health Sciences Center, C 314, 200 East 9th Avenue, Denver, CO 80262, USA
    Curr Oncol Rep 6:216-21. 2004
    ..This article provides an overview of the theoretical basis of ANNs, how they function, their strengths and limitations, and examples of how ANNs have been used to develop predictive models for the management of prostate cancer...
  46. ncbi request reprint Screening for prostate cancer: current recommendations
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA
    Urol Clin North Am 31:219-26. 2004
    ..It is hoped that prospective, randomized, long-term screening studies, such as the PLCO and ERSCP trials, will show improved survival using the admittedly imperfect PSA marker in prostate cancer screening...
  47. ncbi request reprint SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study
    Catherine E Klein
    University of Colorado, Denver, Colorado, USA
    Prostate 52:264-8. 2002
    ..Topotecan is a new topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer...
  48. ncbi request reprint A 72-year-old man with prostate cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 16:1014-6, 1119-21. 2002
  49. doi request reprint The benefits of early androgen blockade
    Paul D Maroni
    The University of Colorado at Denver and Health Sciences Center, Academic Office One Bldg, Aurora, CO 80045, USA
    Best Pract Res Clin Endocrinol Metab 22:317-29. 2008
    ..This review concentrates on high-level evidence to address common clinical situations in advanced and metastatic prostate cancer. Additionally, the side-effects of androgen blockade have become increasingly visible and relevant...
  50. ncbi request reprint The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali Ziada
    UCHSC, 4200 E 9th Ave C 319, Denver, CO, USA
    Prostate 60:332-7. 2004
    ..To investigate the efficacy and toxicity of the antibody to the HER-2/neu receptor (trastuzumab, Herceptin) in the treatment of advanced hormone-refractory prostate cancer (HRPC)...
  51. ncbi request reprint Screening for prostate cancer
    Shandra S Wilson
    Department of Urologic Oncology, Anschutz Cancer Center, Denver, CO, USA
    Clin Prostate Cancer 3:21-5. 2004
    ..These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer...
  52. ncbi request reprint Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer
    Christopher R Porter
    Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington, USA
    Oncology (Williston Park) 17:1395-9; discussion 1399, 1403-6. 2003
    ..With the introduction of more complex prebiopsy variables, ANNs are in a commanding position for use in predictive models. Easy and immediate physician access to these models will be imperative if their full potential is to be realized...
  53. pmc Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities
    Adeyinka O Laiyemo
    Department of Medicine, Howard University College of Medicine, Howard University Cancer Center, Washington, DC 20060, USA
    J Natl Cancer Inst 102:538-46. 2010
    ..It is unclear whether the disproportionately higher incidence and mortality from colorectal cancer among blacks compared with whites reflect differences in health-care utilization or colorectal cancer susceptibility...
  54. ncbi request reprint Intermediate- to high-risk prostate cancer patient treated with radiation therapy
    E David Crawford
    University of Colorado Health Sciences Center, Denver, USA
    Oncology (Williston Park) 18:1105-10. 2004
  55. ncbi request reprint The management of high risk prostate cancer
    Bulent Akduman
    Section of Urologic Oncology, Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 169:1993-8. 2003
    ..There is no consensus on the treatment of these groups of patients. The role of radiotherapy, hormonal therapy or chemotherapy must be defined...
  56. ncbi request reprint Relationship of demographic and clinical factors to free and total prostate-specific antigen
    E P Gelmann
    Lombardi Cancer Center, Georgetown University, Washington, DC 20007-2197, USA
    Urology 58:561-6. 2001
    ..CONCLUSIONS: Demographic (age and race/ethnicity) and clinical (history of benign prostatic disease) variables had a moderate effect on the measures of PSA and fPSA and very little effect on %fPSA...
  57. ncbi request reprint Radiation therapy after radical prostatectomy
    Ali M Ziada
    Division of Urology, University of Colorado, Denver, CO, USA
    ScientificWorldJournal 4:377-81. 2004
  58. ncbi request reprint Surgical management of prostate cancer: optimizing patient selections and clinical outcome
    Paul D Maroni
    Division of Urology, Department of Surgery, University of Colorado Health Sciences Center, Denver, 80252, USA
    Surg Oncol Clin N Am 14:301-19. 2005
  59. doi request reprint A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
    Thomas W Flaig
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Prostate 70:848-55. 2010
    ..The purpose of the current trial was to determine the tissue and blood effects of high-dose silybin-phytosome in prostate cancer patients...
  60. ncbi request reprint A 42-year-old woman with breast cancer
    E David Crawford
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:614; discussion 615-20. 2003
    ..At this point, we recommend tamoxifen, with consideration to adding goserelin (Zoladex) if the patient does not remain amenorrheic. The patient chose to enter the Intergroup trastuzumab trial...
  61. ncbi request reprint Testosterone and the prostate: implications for the treatment of hypogonadal men
    Joshua D Holyoak
    Division of Urology, University of Missouri Health Sciences Center, Columbia, MO 65212, USA
    Curr Urol Rep 9:500-5. 2008
    ..Patients undergoing TRT should be monitored carefully for any evidence of prostatic disease...
  62. ncbi request reprint Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy
    E David Crawford
    Radiation Oncology, Department of Pathology, University of Colorado Health Sciences Center at Fitzsimons, Aurora, CO 80045, USA
    BJU Int 96:999-1004. 2005
    ..To identify the precise location of prostate cancer within the gland and thus possibly permit more aggressive therapy of the lesion, while potentially sparing the noncancerous gland from ablative therapy...
  63. ncbi request reprint Impact of previous local treatment for prostate cancer on subsequent metastatic disease
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Urol 168:1008-12. 2002
    ....
  64. ncbi request reprint Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733
    Celestia S Higano
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Cancer 112:2181-7. 2008
    ..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...
  65. ncbi request reprint Prostate cancer in a man with multiple previous cancers
    Thomas Flaig
    University of Colorado, Health Sciences Center, Aurora, Colorado, USA
    Oncology (Williston Park) 21:611-4. 2007
  66. doi request reprint Dutasteride: novel milestones in prostate cancer chemoprevention
    K O Rove
    University of Colorado, Denver, Colorado, USA
    Drugs Today (Barc) 47:135-44. 2011
    ....
  67. ncbi request reprint A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer
    E D Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO, USA
    Prostate Cancer Prostatic Dis 13:162-7. 2010
    ..With or without treatment, prostate cancer is a significant clinical and economic burden to society. New strategies for treatment or cancer prevention could play a role in reducing this burden...
  68. ncbi request reprint Testosterone replacement therapy and the risk of prostate cancer: a perspective view
    A B Barqawi
    Section Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Int J Impot Res 17:462-3. 2005
    ..This perspective continues the debate, and offers a unique perspective from the vantage point of a uro-oncologist...
  69. doi request reprint Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review
    R Shabsigh
    Division of Urology, Maimonides Medical Center, Brooklyn, NY 11219, USA
    Int J Impot Res 21:9-23. 2009
    ..Testosterone therapy did not have a consistent effect on prostate-specific antigen levels...
  70. ncbi request reprint Controversies regarding screening for prostate cancer
    E David Crawford
    Department of Urologic Oncology, University of Colorado, Denver, CO 80010, USA
    BJU Int 100:5-7. 2007
  71. ncbi request reprint Should routine screening for prostate-specific antigen be recommended?
    Siam Oottamasathien
    Division of Urology, Box c319, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Arch Intern Med 163:661-2; discussion 666. 2003
  72. doi request reprint PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Eur Urol 54:262-73. 2008
    ..Despite the substantive societal impact of prostate cancer, the medical community is currently divided on the balance between benefit and harm of screening for prostate cancer using prostate-specific antigen (PSA)...
  73. ncbi request reprint Minimally invasive surgery in prostate cancer: current and future perspectives
    Bulent Akduman
    University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, Aurora, Colorado 80010, USA
    Cancer J 11:355-61. 2005
    ..In this review we critically discuss the current knowledge and future perspectives of minimally invasive treatment in prostate cancer...
  74. ncbi request reprint Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..We review the current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer...
  75. ncbi request reprint Use of artificial neural networks in prostate cancer
    A Errejon
    ANNs in CaP Project, Denver, Colorado 80209, USA
    Mol Urol 5:153-8. 2001
    ..We review the basic concepts behind ANNs and examine the role of this technology in selected applications in prostate cancer research...
  76. ncbi request reprint Prostate cancer update
    S S Wilson
    Section of Urologic Oncology, Division of Urology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Minerva Urol Nefrol 55:199-204. 2003
    ..Its diagnosis, evaluation, and treatment therapies are constantly evolving. This paper summarizes and clarifies the most up-to-date information on prostate cancer prevention and treatment...
  77. ncbi request reprint Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma
    Thomas D Denberg
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    BJU Int 98:335-40. 2006
    ....
  78. ncbi request reprint The role of LHRH antagonists in the treatment of prostate cancer
    E David Crawford
    Department of Urology, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 23:626-30. 2009
    ..Presently, degarelix is the only LHRH antagonist approved for the treatment of advanced prostate cancer...
  79. doi request reprint Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Urology 75:502-9. 2010
    ..Particular emphasis is placed on the design of the second large-scale trial of a 5alpha-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
  80. ncbi request reprint The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy
    E David Crawford
    Department of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Am J Clin Oncol 29:517-23. 2006
    ..This review will analyze the current state of knowledge of LUTS secondary to RT for prostate cancer and review treatment options for this complication...
  81. ncbi request reprint Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models
    Priya N Werahera
    Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Hum Pathol 35:798-807. 2004
    ..Moreover, our 3-dimensional computer modeling system improves upon other systems: It is more than a simple extension of the planimetric technique, and it is able to demarcate clearly the boundaries of Gleason grades just 1 grade apart...
  82. ncbi request reprint Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning
    Tracy R Glass
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Urol 169:164-9. 2003
    ..Risk stratification is helpful for designing clinical trials and individual treatment, and it should be incorporated into future reports of outcomes of patients with metastatic disease...
  83. ncbi request reprint Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study
    Christopher R Porter
    Department of Urology, State University of New York, Stony Brook, New York, USA
    Urology 60:831-5. 2002
    ..To develop a mathematical model to predict prostate biopsy outcome using readily available clinical variables...
  84. ncbi request reprint Ten-year survival in patients with metastatic prostate cancer
    Catherine M Tangen
    The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Prostate Cancer 2:41-5. 2003
    ..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
  85. ncbi request reprint The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
    ..The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown...
  86. ncbi request reprint Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109
    Isaac J Powell
    Wayne State University Medical Center, Detroit, Michigan, USA
    J Urol 168:2016-9. 2002
    ....
  87. ncbi request reprint Surgical factors influence bladder cancer outcomes: a cooperative group report
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:2781-9. 2004
    ..We evaluated whether surgical factors from patients enrolled onto the study predicted bladder cancer outcomes...
  88. ncbi request reprint Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer
    Ashutosh Tewari
    Josephine Ford Cancer Center and Vattikuti Urology Institute, Henry Ford Health, System, Detroit, MI, USA
    BJU Int 96:29-33. 2005
    ....
  89. ncbi request reprint Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    ..We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer...
  90. pmc Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)
    A Oliver Sartor
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 112:2393-400. 2008
    ..This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial...
  91. ncbi request reprint Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia
    James R Marshall
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Epidemiol Biomarkers Prev 15:1479-84. 2006
    ..Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009...
  92. ncbi request reprint Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa)...
  93. ncbi request reprint Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  94. ncbi request reprint Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA
    BJU Int 99:775-9. 2007
    ..To determine patterns of repeat prostate biopsy in a cohort of men undergoing prostate cancer screening who have a negative initial biopsy...
  95. ncbi request reprint The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Cancer 107:489-96. 2006
    ....
  96. ncbi request reprint Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Donna L Berry
    University of Washington, Seattle, WA 98195 7266, USA
    J Clin Oncol 24:2828-35. 2006
    ..While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms...
  97. ncbi request reprint Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  98. ncbi request reprint Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  99. ncbi request reprint Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men
    Steven A Kaplan
    Diabetes Care 29:749; author reply 749-50. 2006
  100. ncbi request reprint A prospective study of lycopene and tomato product intake and risk of prostate cancer
    Victoria A Kirsh
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 15:92-8. 2006
    ..Dietary lycopene and tomato products may reduce risk of prostate cancer; however, uncertainty remains about this possible association...
  101. ncbi request reprint Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:8724-9. 2005
    ..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...

Research Grants3

  1. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  2. Phytotherapy of Prostateic Symptoms (POPW)
    E Crawford; Fiscal Year: 2007
    ..abstract_text> ..